A Blinded, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of Single and Multiple Doses (7 Days) of ABT-072 and an Open-label Study to Evaluate the Effect of Food on the Pharmacokinetic.
Phase of Trial: Phase I
Latest Information Update: 19 Oct 2010
At a glance
- Drugs ABT 072 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- 19 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2009 Trial location (USA) added as reported by ClinicalTrials.gov record.
- 09 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.